MCID: HYP066
MIFTS: 60

Hyperglycemia

Categories: Blood diseases, Genetic diseases, Metabolic diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Hyperglycemia

MalaCards integrated aliases for Hyperglycemia:

Name: Hyperglycemia 11 75 28 53 5 41 43 14 71

Classifications:



External Ids:

Disease Ontology 11 DOID:4195
MeSH 43 D006943
NCIt 49 C26797
SNOMED-CT 68 144187006
ICD10 31 R73.9
UMLS 71 C0020456

Summaries for Hyperglycemia

MedlinePlus: 41 Hyperglycemia means high blood sugar or glucose. Glucose comes from the foods you eat. Insulin is a hormone that moves glucose into your cells to give them energy. Hyperglycemia happens when your body doesn't make enough insulin or can't use it the right way. People with diabetes can get hyperglycemia from not eating the right foods or not taking medicines correctly. Other problems that can raise blood sugar include infections, certain medicines, hormone imbalances, or severe illnesses.

MalaCards based summary: Hyperglycemia is related to type 1 diabetes mellitus and maturity-onset diabetes of the young, type 2, and has symptoms including fever, dyspnea and vertigo. An important gene associated with Hyperglycemia is MALAT1 (Metastasis Associated Lung Adenocarcinoma Transcript 1), and among its related pathways/superpathways are Metabolism and Nervous system development. The drugs Aripiprazole and Saxagliptin have been mentioned in the context of this disorder. Affiliated tissues include endothelial, liver and brain, and related phenotypes are Decreased viability and homeostasis/metabolism

Wikipedia: 75 Hyperglycemia is a condition in which an excessive amount of glucose circulates in the blood plasma.... more...

Related Diseases for Hyperglycemia

Diseases related to Hyperglycemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1084)
# Related Disease Score Top Affiliating Genes
1 type 1 diabetes mellitus 32.5 PDX1 NOS2 LEP INS IAPP HNF1A
2 maturity-onset diabetes of the young, type 2 32.4 PDX1 KCNJ11 INS HNF1A GCK ABCC8
3 diabetes mellitus, permanent neonatal, 1 32.4 PDX1 KCNJ11 INS GCK ABCC8
4 diabetes mellitus, ketosis-prone 32.3 SLC5A2 KCNJ11 INS GCG DPP4 ALB
5 hyperinsulinism 32.2 PPARG LEP KCNJ11 INSR INS IAPP
6 renal glucosuria 32.2 SLC5A2 INS HNF1A GCG
7 hyperinsulinemic hypoglycemia, familial, 2 32.1 KCNJ11 INS ABCC8
8 abdominal obesity-metabolic syndrome quantitative trait locus 2 32.1 PPARG LEP INS ADIPOQ
9 donohue syndrome 32.0 LEP INSR INS GCK
10 isolated permanent neonatal diabetes mellitus 32.0 PDX1 KCNJ11 INS GCK ABCC8
11 transient neonatal diabetes mellitus 32.0 PDX1 NEUROG3 KCNJ11 INS GCK ABCC8
12 microvascular complications of diabetes 5 31.9 NOS2 INS ALB AKR1B1
13 permanent neonatal diabetes mellitus 31.9 PDX1 NEUROG3 KCNJ11 INS HNF1A GCK
14 neonatal diabetes 31.9 PDX1 NEUROG3 KCNJ11 INS GCK ABCC8
15 hypoglycemia 31.9 SLC5A2 LEP KCNJ11 INSR INS IAPP
16 prediabetes syndrome 31.8 PPARG LEP KCNJ11 INSR INS IAPP
17 gestational diabetes 31.6 PPARG PDX1 LEP KCNJ11 INSR INS
18 lipid metabolism disorder 31.6 SLC5A2 PPARG LEP INSR INS GCG
19 abdominal obesity-metabolic syndrome 1 31.6 PPARG LEP INS GCK GCG ADIPOQ
20 myocardial infarction 31.5 PPARG PDX1 NOS2 LEP INS DPP4
21 non-alcoholic fatty liver disease 31.5 PPARG LEP INSR INS GCG DPP4
22 nutritional deficiency disease 31.4 LEP ALB ADIPOQ
23 leptin deficiency or dysfunction 31.4 PPARG LEP INS IAPP GCG DPP4
24 vascular disease 31.4 PPARG NOS2 LEP INS ALB ADIPOQ
25 atherosclerosis susceptibility 31.4 PPARG NOS2 LEP INS ALB ADIPOQ
26 diabetic neuropathy 31.3 INS ALB AKR1B1
27 type 2 diabetes mellitus 31.3 SLC5A2 PPARG PDX1 NEUROG3 LEP KCNJ11
28 cardiovascular system disease 31.2 PPARG NOS2 LEP INS ALB ADIPOQ
29 glucose intolerance 31.2 PPARG NEUROG3 LEP KCNJ11 INSR INS
30 lipoprotein quantitative trait locus 31.2 PPARG NOS2 INS GCG ALB ADIPOQ
31 microvascular complications of diabetes 3 31.2 MALAT1 INS ALB AKR1B1
32 lactic acidosis 31.1 SLC5A2 INS GCG DPP4 ALB
33 body mass index quantitative trait locus 11 31.1 SLC5A2 PPARG LEP KCNJ11 INSR INS
34 peripheral nervous system disease 31.1 PPARG LEP INS GCG DPP4 ALB
35 kidney disease 31.1 PPARG LEP INSR INS HNF1A DPP4
36 conn's syndrome 31.1 PPARG LEP INS GCG ALB ADIPOQ
37 familial hyperlipidemia 31.1 PPARG LEP INS GCK ADIPOQ
38 monogenic diabetes 31.0 KCNJ11 INS HNF1A GCK ABCC8
39 urinary tract infection 31.0 SLC5A2 INS GCG DPP4 ALB
40 diabetes mellitus 31.0 SLC5A2 PPARG PDX1 NOS2 NEUROG3 MALAT1
41 autonomic neuropathy 31.0 INS GCG ALB AKR1B1
42 hypertension, essential 31.0 SLC5A2 PPARG NOS2 LEP INSR INS
43 retinal vascular disease 30.9 INS ALB AKR1B1
44 polycystic ovary syndrome 30.9 PPARG LEP INSR INS ADIPOQ
45 hyperuricemia 30.9 PPARG LEP INS ALB
46 insulin-like growth factor i 30.9 LEP INSR INS
47 adult syndrome 30.8 PPARG LEP INS ADIPOQ
48 apnea, obstructive sleep 30.8 LEP INS GCG ALB ADIPOQ
49 sleep apnea 30.8 PPARG LEP INS ALB ADIPOQ
50 central pontine myelinolysis 30.7 INS ALB

Graphical network of the top 20 diseases related to Hyperglycemia:



Diseases related to Hyperglycemia

Symptoms & Phenotypes for Hyperglycemia

UMLS symptoms related to Hyperglycemia:


fever; dyspnea; vertigo; cachexia; headache; syncope; cyanosis; edema; icterus; seizures; signs and symptoms; signs and symptoms, digestive; hot flushes; symptoms

GenomeRNAi Phenotypes related to Hyperglycemia according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00106-A-0 9.58 UNC13B
2 Decreased viability GR00221-A-1 9.58 GCK INSR PPARG UNC13B
3 Decreased viability GR00221-A-2 9.58 GCK INSR PPARG UNC13B
4 Decreased viability GR00221-A-3 9.58 GCK INSR PPARG UNC13B
5 Decreased viability GR00221-A-4 9.58 GCK INSR PPARG UNC13B
6 Decreased viability GR00386-A-1 9.58 PPARG

MGI Mouse Phenotypes related to Hyperglycemia:

45 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.41 ABCC8 ADIPOQ AKR1B1 ALB DPP4 GCG
2 renal/urinary system MP:0005367 10.36 ADIPOQ AKR1B1 ALB GCG GCK HNF1A
3 growth/size/body region MP:0005378 10.33 ABCC8 ADIPOQ AKR1B1 DPP4 GCG GCK
4 endocrine/exocrine gland MP:0005379 10.27 ABCC8 ADIPOQ ALB DPP4 GCG GCK
5 muscle MP:0005369 10.19 ADIPOQ ALB HNF1A INS INSR KCNJ11
6 no phenotypic analysis MP:0003012 10.18 ABCC8 HNF1A INS KCNJ11 MALAT1 NEUROG3
7 liver/biliary system MP:0005370 10.18 ADIPOQ ALB GCK HNF1A INS INSR
8 adipose tissue MP:0005375 10.16 ADIPOQ HNF1A INS INSR KCNJ11 LEP
9 cellular MP:0005384 10.07 ADIPOQ ALB DPP4 GCK HNF1A INS
10 digestive/alimentary MP:0005381 10.02 ALB GCG HNF1A INS INSR LEP
11 cardiovascular system MP:0005385 9.9 ABCC8 ADIPOQ ALB DPP4 GCK INS
12 immune system MP:0005387 9.73 ADIPOQ ALB DPP4 IAPP INS INSR
13 mortality/aging MP:0010768 9.53 ADIPOQ AKR1B1 ALB DPP4 GCG GCK

Drugs & Therapeutics for Hyperglycemia

Drugs for Hyperglycemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 328)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
2
Saxagliptin Approved Phase 4 361442-04-8 11243969
3
Metformin Approved Phase 4 1115-70-4, 657-24-9 4091
4
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
5
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
6
Hydrocortisone succinate Approved Phase 4 2203-97-6 3643
7
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
8
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 3640 5754
9
Insulin detemir Approved Phase 4 169148-63-4 16137271
10
Liraglutide Approved Phase 4 204656-20-2 44147092 16134956
11
Dapagliflozin Approved Phase 4 461432-26-8 9887712
12
Somatostatin Approved, Investigational Phase 4 38916-34-6, 51110-01-1 53481605 16129706
13
Pasireotide Approved Phase 4 396091-73-9 56841596 9941444
14
Exenatide Approved, Investigational Phase 4 141758-74-9 45588096
15
Insulin glulisine Approved Phase 4 207748-29-6
16
Losartan Approved Phase 4 114798-26-4 3961
17
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 11128-99-7, 4474-91-3 172198
18
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
19
Olanzapine Approved, Investigational Phase 4 132539-06-1 135398745 4585
20
Remifentanil Approved Phase 4 132875-61-7 60815
21
Acarbose Approved, Investigational Phase 4 56180-94-0 441184 444254
22
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1, 93107-08-5 2764
23
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
24
Ofloxacin Approved Phase 4 82419-36-1 4583
25
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
26
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
27
Acetylsalicylic acid Approved, Vet_approved Phase 4 50-78-2 2244
28
Dulaglutide Approved, Investigational Phase 4 923950-08-7
29
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
30
Dexmedetomidine Approved, Experimental, Vet_approved Phase 4 86347-14-0, 113775-47-6 68602 5311068
31 English walnut Approved Phase 4
32
Caffeine Approved Phase 4 58-08-2 2519
33
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
34
Heparin, bovine Approved, Investigational, Withdrawn Phase 4 9005-49-6 22833565 9812414 772
35
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
36
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
37
Prednisolone Approved, Vet_approved Phase 4 50-24-8 4894 5755
38
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5 1875
39
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 4159 6741
40
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
41
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7 4897
42 Hormones Phase 4
43 Hormone Antagonists Phase 4
44 Dopamine agonists Phase 4
45 Serotonin Receptor Agonists Phase 4
46 Serotonin 5-HT1 Receptor Agonists Phase 4
47 Omega 3 Fatty Acid Phase 4
48 Sodium-Glucose Transporter 2 Inhibitors Phase 4
49 Insulin, Short-Acting Phase 4
50 Appetite Depressants Phase 4

Interventional clinical trials:

(show top 50) (show all 586)
# Name Status NCT ID Phase Drugs
1 Optimal Insulin Correction Factor in Post- High Intensity Exercise Hyperglycemia in Adults With Type 1 Diabetes: The FIT Study Unknown status NCT03057470 Phase 4 50% bolus insulin correction;100% bolus insulin correction;150% bolus insulin correction
2 Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia by Aripiprazole Add-on Therapy in the Treatment of Schizophrenia and Bipolar Disorder: An Open-Label Trial Unknown status NCT00541554 Phase 4 Abilify (aripiprazole)
3 A Pilot Study of Outpatient Discharge Therapy With Saxagliptin + Metformin XR or Sulphonylurea for Recently Diagnosed Type 2 Diabetes Presenting With Severe Hyperglycemia Unknown status NCT01267448 Phase 4 Glipizide XL;Saxagliptin + Metformin XR;Metformin XR
4 Randomized Controlled Clinical Study of Intensive Versus Nonintensive Insulin Therapy for Hyperglycemia After Traumatic Brain Injury Unknown status NCT02161055 Phase 4 Insulin
5 ß-Cell Function and Glycemic Control of Basal Insulin, Metformin or Sitagliptin in Newly Diagnosed Type 2 Diabetic Patients With Moderate Hyperglycemia Unknown status NCT01717911 Phase 4 Insulin;Metformin;Sitagliptin
6 Perioperative Continuation of Metformin Therapy in Patients With Typ 2 Diabetes Mellitus Undergoing Non-cardiac Surgery Unknown status NCT04284722 Phase 4 Metformin Hydrochloride
7 A Randomized Controlled Trial Comparing SGC and Conventional Empiric Treatment for Glucose Control in Critically Ill Patients With Mechanical Ventilation in ICU Unknown status NCT02491346 Phase 4
8 The Therapeutic Effects of Combination of Insulin With Berberine on the Patients With Stess Hyperlipemia:a Prospective, Double Blind, Randomized, Placebo-controlled, Single-center Clinical Trial Unknown status NCT02806999 Phase 4 Berberine; Insulin;Insulin
9 Randomised Clinical Trial to Evaluate the Obtention of Blood Samples Through an Arterial Catheter to Monitor Glycose Levels Unknown status NCT01176279 Phase 4
10 Efficacy and Safety of Liraglutide-bolus (Liraglutide Plus Prandial Insulin) Versus Glargine-bolus Therapy in Overweight / Obese Patients With Uncontrolled Type 2 Diabetes (LiraGooD)--A Multicenter Randomized Controlled Study Unknown status NCT03087032 Phase 4 Liraglutide;insulin glargine
11 Double-blind and Placebo-controlled Study on Intervention Effect of n-3 Fatty Acids on Glucose and Lipid Homeostasis Disorders in Obese/Diabetic Populations Unknown status NCT03708887 Phase 4 Low dose omega-3 fatty acid supplementation;High dose omega-3 fatty acid supplementation;Control drug
12 Reducing Postprandial Hyperglycemia With Adjuvant Premeal Pramlintide and Postmeal Insulin in Children With Type 1 Diabetes Mellitus. Completed NCT00442767 Phase 4 Insulin;Pramlintide + Insulin
13 Carvedilol vs.Metoprolol: A Comparison of Effects on Endothelial Function and Oxidative Stress in Response to Acute Hyperglycemia in Patients With Type 2 Diabetes and Hypertension Completed NCT00642434 Phase 4 carvedilol;metoprolol
14 Hyperglycemia and Effects of Daily 100 Milligrams Versus 200 Milligrams of Hydrocortisone Therapy in Patients With Septic Shock: A Double-Blind Randomized Controlled Trial Completed NCT02266264 Phase 4 Hydrocortisone
15 NPH and Regular Insulin in the Treatment of Inpatient Hyperglycemia: Comparison of 3 Basal-bolus Regimens Completed NCT02758522 Phase 4 Once-daily Insulin;Twice-daily Insulin;Triple-daily Insulin
16 Prevention of Stress Hyperglycemia With the Use of DPP-4 Inhibitors in Non-diabetic Patients Undergoing Non-cardiac Surgery, a Pilot Study Completed NCT02741687 Phase 4 Sitagliptin;Placebo;Supplemental insulin (insulin lispro);Supplemental insulin (insulin aspart);Long acting basal insulin (insulin detemir);Long acting basal insulin (insulin glargine)
17 Sitagliptin for the Prevention and Treatment of Hyperglycemia in Patients With Type 2 Diabetes Undergoing Cardiac Surgery Completed NCT02556918 Phase 4 Sitagliptin;Placebo;Regular Human Insulin;Insulin glargine;Supplemental insulin (Insulin lispro);Supplemental insulin (Insulin aspart)
18 A Multi-center, Randomized, Open-label, Phase IV Study to Investigate the Management of Pasireotide-induced Hyperglycemia With Incretin Based Therapy or Insulin in Adult Patients With Cushing's Disease or Acromegaly Completed NCT02060383 Phase 4 Pasireotide s.c.;Sitagliptin;Liraglutide;Insulin;Pasireotide LAR;Metformin
19 Management of Diabetic Ketoacidosis in Children: Does Early Glargine Prevent Rebound Hyperglycemia? Completed NCT03107208 Phase 4 Glargine
20 Benefits of Insulin Supplementation for Correction of Hyperglycemia in Patients With Type 2 Diabetes Treated With Basal Bolus Insulin Regimen Completed NCT02408120 Phase 4 Insulin glargine;Insulin aspart;Supplemental insulin aspart
21 Management of Hyperglycemia in the Emergency Room: A Randomized Clinical Trial of a Subcutaneous Insulin Aspart Protocol Coupled With Rapid Initiation of Basal Bolus Insulin Prior to Hospital Admission Versus Usual Care Completed NCT00591227 Phase 4 insulin aspart;insulin detemir
22 Hyperglycemia and Its Effect After Acute Myocardial Infarction on Cardiovascular Outcomes in Patients With Type 2 Diabetes (HEART2D) Completed NCT00191282 Phase 4 Insulin lispro;Human insulin isophane suspension (NPH);Insulin glargine;Human insulin isophane suspension;Human insulin 30/70
23 Sitagliptin for the Prevention and Treatment of Stress Hyperglycemia in Non-Diabetic Patients Undergoing Cardiac Surgery Completed NCT02443402 Phase 4 Sitagliptin;Placebo;Regular Human Insulin;Insulin glargine;Supplemental insulin (Insulin lispro);Supplemental insulin (Insulin aspart)
24 Efficacy and Safety of Human Insulin Versus Analog Insulin in Hospitalized Acute Stroke Patients With Hyperglycemia: a Randomized, Open-label, Single Center Trial Completed NCT04834362 Phase 4 Analog Insulin;Human insulin
25 "Safety and Efficacy of Acthar Gel on Albuminuria and Urinary Transforming Growth Factor Excretion in Type I or Type II Diabetics Requiring Medical Treatment of Hyperglycemia With Nephrotic Range Proteinuria: A Pilot Study" Completed NCT01028287 Phase 4 ACTH
26 Exenatide (Byetta) Vs Pramlintide (Symlin): Role in Post-prandial Hyperglycemia Completed NCT01269047 Phase 4 Pramlintide;Exenatide;Insulin
27 The Management of Glucocorticoid-Induced Hyperglycemia in Hospitalized Patients Completed NCT01810952 Phase 4 Glargine insulin;Lispro insulin;NPH Insulin
28 The Effect of Postprandial Hyperglycemia on the Arterial Stiffness in Patients With Type 2 Diabetes Completed NCT01159938 Phase 4 Lispro
29 Effect of Low-Dose Dexamethasone on the Incidence of Hyperglycemia Following Surgery Completed NCT01545700 Phase 4 Control-saline;Dexamethasone 4 mg;Dexamethasone 8 mg;Control saline
30 Glucose Control for Glucocorticoid Induced Hyperglycemia During Chemotherapy Completed NCT02155374 Phase 4 Sliding scale insulin;Intermediate acting insulin;Glucose lowering medication;Chemotherapy
31 Hospital Insulin Protocol Aims for Glucose Control in Corticosteroid-induced Hyperglycemia Completed NCT01184014 Phase 4 NPH insulin plus Complete Insulin Orders;Complete Insulin Orders
32 Protocol Merck 318-00: A Double-Blind, Placebo-Controlled, Randomized, Parallel, Clinical Trial To Study The Effect Of Losartan Potassium On Endothelial Dysfunction And Insulin Resistance In Obese Patients With Impaired Fasting Glucose Completed NCT00675987 Phase 4 losartan;Placebo control
33 Strict Glycemic Control by Insulin Infusion:Observations on Emergency Department Initiation Completed NCT00779701 Phase 4 Insulin
34 Effect of Different Enteral Nutrition Formulas on Glucose Homeostasis Completed NCT03012867 Phase 4
35 Randomized Controlled Trial of Nurse-directed vs Nomogram-directed Intensive Glucose Control in the CVICU Completed NCT00636714 Phase 4
36 Basal Bolus Regimen With Insulin Analogs Versus Human Insulin in Medical Patients With Type 2 Diabetes: A Randomized Controlled Trial in Paraguay Completed NCT02278913 Phase 4 Basal Bolus (Glargine and Glulisine);Human Insulin
37 Effects of Insulin Treatment on Postprandial Platelet Activation in Patients With NIDDM: a Placebo-controlled Dose-response Study With Insulin Aspart (Novorapid®) Completed NCT00771693 Phase 4 Insulin aspart (Novorapid®)
38 Efficacy of a Continuous GLP-1 Infusion in Comparison to a Structured Insulin Infusion Protocol to Reach Normoglycemia in Non-Fasted Type 2 Diabetic Patients Completed NCT00859079 Phase 4 GLP-1;Human regular insulin intravenously
39 Intensive Exenatide Therapy in Hyperglycemic Patients Admitted to the Coronary Intensive Care Unit Completed NCT00736229 Phase 4 Exenatide
40 Comparative Trial Between Insulin Glargine Plus Supplemental Glulisine (Apidra) Versus Sliding Scale Regular Insulin In Hospitalized Patients With Type 2 Diabetes Completed NCT00394407 Phase 4 sliding scale regular insulin;glargine basal insulin and glulisine prandial insulin
41 Randomized, Double-blind, Placebo-controlled Trial on the Effectiveness and Safety of Dapagliflozin for Blood Glucose Control During Glucocorticoid Treatment for Acute Exacerbation COPD Completed NCT02253121 Phase 4 Dapagliflozin;Sliding scale insulin
42 The Effect of Insulin Glargine on Glycemic Control, Morbidity, and Length of Stay in Hospitalized Subjects With Diabetes Receiving Enteral Nutrition Completed NCT00177398 Phase 4 Glargine insulin vs regular insulin
43 Effect of Acarbose on Postprandial Lipoprotein Levels in Glucose Intolerant Patients Completed NCT02355509 Phase 4 Acarbose;Placebo
44 Effect of Crocus Sativus (Saffron) and Berberis Vulgaris (Barberry Fruit) on Metabolic Syndrome Completed NCT01625442 Phase 4 Saffron tablet;Barberry tablet;Placebo
45 RAndomized Study of Basal Bolus Insulin Therapy in the Inpatient Management of Patients With Type 2 Diabetes Undergoing General Surgery (RABBIT 2 Surgery) Completed NCT00596687 Phase 4 Insulin glargine;Regular insulin;Insulin glulisine
46 Ketosis-Prone Diabetes in African Americans: Predictive Markers, Underlying Mechanisms, and Treatment Outcomes: The Effects of Metformin vs. Sitagliptin on Beta-Cell Preservation in Obese Subjects With Ketosis-Prone Type 2 Diabetes Mellitus Completed NCT01099618 Phase 4 metformin;placebo;Sitagliptin
47 A Multi-Center, Open Label Randomized Stratified Controlled Trial of the Effects of Blood Glucose Management on 90-Day All-Cause Mortality in a Heterogenous Population of Intensive Care Unit (ICU) Patients. Completed NCT00220987 Phase 4
48 Intensive Insulin Therapy in Non-diabetic Patients With Acute Myocardial Infarction and Hyperglycaemia Completed NCT00362778 Phase 4 Insulin
49 Conversion of Hyperglycemic Patients Being Treated With Intravenous Insulin Infusions to Lantus Insulin Completed NCT00338104 Phase 4 insulin glargine
50 Independent Investigator Grant Study-Comparative Effects of Chronic Treatment With Olanzapine and Risperidone on Glucose and Lipid Metabolism Completed NCT00287820 Phase 4 Olanzapine;olanzapine;risperidone

Search NIH Clinical Center for Hyperglycemia

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Insulin
insulin beef, isophane
insulin beef-pork, isophane
insulin degludec
Insulin Glargine
insulin human, isophane
Insulin Lispro
insulin pork, isophane
Insulin, Aspart Protamine, Human
Insulin, Aspart, Human
Insulin, Glulisine, Human
Insulin, Prompt Zinc, Beef
Insulin, Prompt Zinc, Beef-Pork
Insulin, Prompt Zinc, Pork
Insulin, Protamine Lispro, Human
insulin, protamine zinc, beef
Insulin, Protamine Zinc, Beef-Pork
Insulin, Protamine Zinc, Pork
Insulin, Regular, Beef
insulin, regular, beef-pork
Insulin, Regular, Pork
Insulin, Zinc, Human
Insulin, Zinc, Pork
INSULIN,DETEMIR,HUMAN
INSULIN,REGULAR,HUMAN BUFFERED
Lente Insulin, Beef
Lente Insulin, Beef-Pork
Regular Insulin, Human
Ultralente Insulin, Beef
Ultralente Insulin, Beef-Pork
Ultralente Insulin, Human

Cochrane evidence based reviews: hyperglycemia

Genetic Tests for Hyperglycemia

Genetic tests related to Hyperglycemia:

# Genetic test Affiliating Genes
1 Hyperglycemia 28

Anatomical Context for Hyperglycemia

Organs/tissues related to Hyperglycemia:

MalaCards : Endothelial, Liver, Brain, Bone Marrow, Heart, Pancreas, Kidney

Publications for Hyperglycemia

Articles related to Hyperglycemia:

(show top 50) (show all 30402)
# Title Authors PMID Year
1
Nutraceutical Eriocitrin (Eriomin) Reduces Hyperglycemia by Increasing Glucagon-Like Peptide 1 and Downregulates Systemic Inflammation: A Crossover-Randomized Clinical Trial. 62 41
35796695 2022
2
Efficacy and Safety of Omija (Schisandra chinensis) Extract Mixture on the Improvement of Hyperglycemia: A Randomized, Double-Blind, and Placebo-Controlled Clinical Trial. 62 41
35956334 2022
3
Null mutations of NEUROG3 are associated with delayed-onset diabetes mellitus. 5
31805014 2020
4
A Comprehensive Structure-Function Study of Neurogenin3 Disease-Causing Alleles during Human Pancreas and Intestinal Organoid Development. 5
31178402 2019
5
A novel NEUROG3 mutation in neonatal diabetes associated with a neuro-intestinal syndrome. 5
28940958 2018
6
Hypogonadotropic Hypogonadism and Short Stature in Patients with Diabetes Due to Neurogenin 3 Deficiency. 5
27533310 2016
7
Neonatal diabetes and congenital malabsorptive diarrhea attributable to a novel mutation in the human neurogenin-3 gene coding sequence. 5
21490072 2011
8
Permanent Neonatal Diabetes and Enteric Anendocrinosis Associated With Biallelic Mutations in NEUROG3. 5
21378176 2011
9
Mutant neurogenin-3 in congenital malabsorptive diarrhea. 5
16855267 2006
10
Circulating osteogenic progenitors and osteoclast precursors are associated with long-term glycemic control, sex steroids, and visceral adipose tissue in men with type 2 diabetes mellitus. 41
36171900 2022
11
Enhanced proliferation and migration of vascular smooth muscle cells in response to vascular injury under hyperglycemic conditions is controlled by beta3 integrin signaling. 53 62
20184965 2010
12
[Endothelial dysfunction in diabetes]. 53 62
20446576 2010
13
Exendin-4 increases blood glucose levels acutely in rats by activation of the sympathetic nervous system. 53 62
20197503 2010
14
C-reactive protein -717C>T genetic polymorphism associates with esophagectomy-induced stress hyperglycemia. 53 62
20145925 2010
15
Insulin-like growth factor-I-stimulated insulin receptor substrate-1 negatively regulates Src homology 2 domain-containing protein-tyrosine phosphatase substrate-1 function in vascular smooth muscle cells. 53 62
20207740 2010
16
Hyperglycemia and hypoxia are interrelated in their teratogenic mechanism: studies on cultured rat embryos. 53 62
20127827 2010
17
The effect of insulin signaling on female reproductive function independent of adiposity and hyperglycemia. 53 62
20176725 2010
18
Turning glucosuria into a therapy: Efficacy and safety with SGLT2 inhibitors. 53 62
20425568 2010
19
Bone marrow transplantation temporarily improves pancreatic function in streptozotocin-induced diabetes: potential involvement of very small embryonic-like cells. 53 62
20110858 2010
20
The RAGE axis: a fundamental mechanism signaling danger to the vulnerable vasculature. 53 62
20299674 2010
21
Addressing hyperglycemia from hospital admission to discharge. 53 62
20078323 2010
22
Glucagon-like peptide-1 response to meals and post-prandial hyperglycemia in Type 2 diabetic patients. 53 62
19783893 2010
23
Type 2 diabetes: postprandial hyperglycemia and increased cardiovascular risk. 53 62
20448799 2010
24
AMPK as a metabolic tumor suppressor: control of metabolism and cell growth. 53 62
20222801 2010
25
Hyperglycemia adversely modulates endothelial nitric oxide synthase during anesthetic preconditioning through tetrahydrobiopterin- and heat shock protein 90-mediated mechanisms. 53 62
20124983 2010
26
Lifestyle, anthropometric, and obesity-related physiologic determinants of insulin-like growth factor-1 in the Third National Health and Nutrition Examination Survey (1988-1994). 53 62
20159489 2010
27
Association between ischemia modified albumin, inflammation and hyperglycemia in type 2 diabetes mellitus. 53 62
19968982 2010
28
Pdx1-transfected adipose tissue-derived stem cells differentiate into insulin-producing cells in vivo and reduce hyperglycemia in diabetic mice. 53 62
19757377 2010
29
Naturally occurring glucokinase mutations are associated with defects in posttranslational S-nitrosylation. 53 62
19934346 2010
30
Polygenic risk variants for type 2 diabetes susceptibility modify age at diagnosis in monogenic HNF1A diabetes. 53 62
19794065 2010
31
Protective effects of grape seed proanthocyanidin extracts on cerebral cortex of streptozotocin-induced diabetic rats through modulating AGEs/RAGE/NF-kappaB pathway. 53 62
20495289 2010
32
Acute hyperglycemia produces transient improvement in glucose transporter type 1 deficiency. 53 62
20186957 2010
33
Prevention of hepatic steatosis and hepatic insulin resistance by knockdown of cAMP response element-binding protein. 53 62
19945407 2009
34
"Blinding" of AMP-dependent kinase by methylglyoxal: a mechanism that allows perpetuation of hepatic insulin resistance? 53 62
19643547 2009
35
Long-term inhibition of the glucagon receptor with a monoclonal antibody in mice causes sustained improvement in glycemic control, with reversible alpha-cell hyperplasia and hyperglucagonemia. 53 62
19720878 2009
36
Mechanisms of gastric emptying disturbances in chronic and acute inflammation of the distal gastrointestinal tract. 53 62
20501434 2009
37
Low plasma adiponectin level, white blood cell count and Helicobacter pylori titre independently predict abnormal pancreatic beta-cell function. 53 62
19747747 2009
38
Update on mutations in glucokinase (GCK), which cause maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemic hypoglycemia. 53 62
19790256 2009
39
Targeting SGK1 in diabetes. 53 62
19764891 2009
40
Contribution of glucose tolerance and gender to cardiac adiposity. 53 62
19820028 2009
41
High glucose-induced oxidative stress alters estrogen effects on ERalpha and ERbeta in human endothelial cells: reversal by AMPK activator. 53 62
19635557 2009
42
Central leptin gene therapy ameliorates diabetes type 1 and 2 through two independent hypothalamic relays; a benefit beyond weight and appetite regulation. 53 62
19647774 2009
43
Foxo1 links hyperglycemia to LDL oxidation and endothelial nitric oxide synthase dysfunction in vascular endothelial cells. 53 62
19584310 2009
44
The adrenergic-fatty acid load in heart failure. 53 62
19850204 2009
45
Maturity-onset diabetes of the young in children with incidental hyperglycemia: a multicenter Italian study of 172 families. 53 62
19564454 2009
46
Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors. 53 62
19758106 2009
47
Combined effects of hyperglycemic conditions and HIV-1 Nef: a potential model for induced HIV neuropathogenesis. 53 62
19878567 2009
48
RAGE: therapeutic target and biomarker of the inflammatory response--the evidence mounts. 53 62
19477910 2009
49
Posttransplantation hypomagnesemia and its relation with immunosuppression as predictors of new-onset diabetes after transplantation. 53 62
19624560 2009
50
Mild fasting hyperglycemia in children: high rate of glucokinase mutations and some risk of developing type 1 diabetes mellitus. 53 62
19309449 2009

Variations for Hyperglycemia

ClinVar genetic disease variations for Hyperglycemia:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 NEUROG3 NM_020999.4(NEUROG3):c.394A>T (p.Ile132Phe) SNV Likely Pathogenic
1162203 GRCh37: 10:71332406-71332406
GRCh38: 10:69572650-69572650
2 KLF11 NM_003597.5(KLF11):c.23G>A (p.Gly8Asp) SNV Uncertain Significance
523462 rs1553312826 GRCh37: 2:10183866-10183866
GRCh38: 2:10043739-10043739

Copy number variations for Hyperglycemia from CNVD:

6
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 44162 10 52900000 70600000 Copy number TFAM Hyperglycemia

Expression for Hyperglycemia

Search GEO for disease gene expression data for Hyperglycemia.

Pathways for Hyperglycemia

Pathways related to Hyperglycemia according to GeneCards Suite gene sharing:

(show all 25)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.73 PPARG KCNJ11 INS GCK GCG ALB
2
Show member pathways
13.6 ADIPOQ GCK HNF1A IAPP INS LEP
3
Show member pathways
12.39 KCNJ11 INS GCG ADIPOQ ABCC8
4
Show member pathways
12.36 SLC5A2 KCNJ11 GCK ABCC8
5 12.24 SLC5A2 PPARG PDX1 INSR INS HNF1A
6
Show member pathways
12.11 LEP INS GCG DPP4
7
Show member pathways
12.09 NOS2 LEP INSR INS
8
Show member pathways
12.01 LEP INSR INS ADIPOQ
9 11.96 PDX1 NEUROG3 INS ALB
10 11.95 PPARG LEP INS HNF1A ADIPOQ
11
Show member pathways
11.9 PDX1 INSR INS HNF1A GCK
12 11.76 PPARG LEP INS ADIPOQ
13
Show member pathways
11.69 PDX1 NEUROG3 INS IAPP HNF1A GCK
14
Show member pathways
11.68 PPARG NOS2 AKR1B1
15 11.59 NOS2 LEP GCK
16
Show member pathways
11.54 LEP GCG DPP4
17 11.48 LEP KCNJ11 ABCC8
18 11.42 LEP INSR INS ADIPOQ
19 11.4 LEP INSR INS
20
Show member pathways
11.13 INS INSR LEP
21
Show member pathways
11.13 PDX1 KCNJ11 INS HNF1A GCK ALB
22 11.07 PPARG LEP ADIPOQ
23 11.01 ADIPOQ INSR LEP PPARG
24 10.97 ADIPOQ INSR KCNJ11 PDX1
25 10.61 PDX1 KCNJ11 INSR INS HNF1A GCK

GO Terms for Hyperglycemia

Cellular components related to Hyperglycemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 inward rectifying potassium channel GO:0008282 8.92 KCNJ11 ABCC8

Biological processes related to Hyperglycemia according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of MAPK cascade GO:0043410 10.23 LEP INSR INS IAPP
2 response to hypoxia GO:0001666 10.22 NOS2 LEP DPP4 ADIPOQ
3 response to xenobiotic stimulus GO:0009410 10.15 ABCC8 ADIPOQ KCNJ11 PDX1 PPARG
4 response to activity GO:0014823 10.07 LEP GCG ADIPOQ
5 carbohydrate metabolic process GO:0005975 10.06 SLC5A2 INSR INS GCK AKR1B1
6 positive regulation of protein kinase B signaling GO:0051897 10.02 LEP INSR INS IAPP HNF1A
7 cellular response to insulin stimulus GO:0032869 10.02 PPARG LEP INSR GCK ADIPOQ
8 insulin secretion GO:0030073 10.01 PDX1 LEP HNF1A
9 positive regulation of insulin secretion GO:0032024 10 PDX1 HNF1A GCK
10 positive regulation of glucose import GO:0046326 10 INSR INS ADIPOQ
11 placenta development GO:0001890 9.97 PPARG LEP HNF1A
12 positive regulation of respiratory burst GO:0060267 9.92 INSR INS
13 exocrine pancreas development GO:0031017 9.91 PDX1 INSR
14 negative regulation of gluconeogenesis GO:0045721 9.91 INS GCK ADIPOQ
15 transdifferentiation GO:0060290 9.88 NEUROG3 PDX1
16 positive regulation of glycogen biosynthetic process GO:0045725 9.88 GCK INS INSR
17 positive regulation of fatty acid metabolic process GO:0045923 9.87 PPARG ADIPOQ
18 prostaglandin secretion GO:0032310 9.86 NOS2 LEP
19 regulation of insulin secretion GO:0050796 9.85 NOS2 LEP KCNJ11 GCK GCG
20 positive regulation of developmental growth GO:0048639 9.81 LEP INSR
21 renal glucose absorption GO:0035623 9.8 HNF1A SLC5A2
22 negative regulation of acute inflammatory response GO:0002674 9.78 PPARG INS
23 detection of glucose GO:0051594 9.78 GCK PDX1
24 positive regulation of insulin secretion involved in cellular response to glucose stimulus GO:0035774 9.73 ABCC8 GCG KCNJ11 PDX1
25 glucose metabolic process GO:0006006 9.73 ADIPOQ GCK INS KCNJ11 LEP PDX1
26 glucose homeostasis GO:0042593 9.58 PPARG PDX1 LEP INSR INS HNF1A

Molecular functions related to Hyperglycemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.32 LEP INS IAPP GCG ADIPOQ
2 ATP-activated inward rectifier potassium channel activity GO:0015272 9.26 KCNJ11 ABCC8

Sources for Hyperglycemia

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....